证券代码：000576 证券简称：甘化科工 公告编号：2024-37 广东甘化科工股份有限公司关于 2021 年限制性股票激励计 划首次授予第三个解除限售期及预留授予第二个解除限售 期解除限售条件未成就暨回购注销部分限制性股票的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次拟回购注销的限制性股票数量173.1058万股，回购价格 为原回购价格经调整后的回购价格人民币5.23元/股。 2、回购注销完成后，公司总股本将由438,149,272股变更为 436,418,214股。 3、本次回购注销事项尚需提交公司股东大会审议。 广东甘化科工股份有限公司（以下简称"公司"）于 2024年5 月21日召开第十一届董事会第六次会议及第十一届监事会第五次会 议，审议通过了《关于2021年限制性股票激励计划首次授予第三个解 除限售期及预留授予第二个解除限售期解除限售条件未成就暨回购 注销部分限制性股票的议案》。鉴于公司2021年限制性股票激励计划 首次授予第三个解除限售期及预留授予第二个解除限售期的解除限 售条件均未成就，同时首次授予及预留授予激励 ...

证券代码：000576 证券简称：甘化科工 公告编号：2024-34 广东甘化科工股份有限公司 关于股份回购进展情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 广东甘化科工股份有限公司（以下简称"公司"）于 2024 年 3 月 4 日召开第十一届董事会第二次会议，审议通过了《关于以集中竞价交易方 式回购公司股份方案的议案》。董事会同意公司以自有资金通过集中竞价 交易方式回购公司股份。回购资金总额为不低于人民币 2,500 万元且不超 过人民币 5,000 万元（均含本数），回购股份的价格不超过人民币 10.00 元/股（含），具体回购股份数量以回购期满时实际回购的股份数量为准。 本次回购股份的实施期限为自公司董事会审议通过回购股份方案之日起 不超过 12 个月。详情请参阅公司于 2024 年 3 月 5 日在《中国证券报》 《 证 券 时 报 》《 上 海 证 券 报 》《 证 券 日 报 》 及 巨 潮 资 讯 网 （http://www.cninfo.com.cn）披露的《关于以集中竞价交易方式回购公 司股份方案的公告》。 一、回购公司股份的 ...

Financial Performance - The company's operating revenue for Q1 2024 was ¥77,848,729.29, a decrease of 8.31% compared to ¥84,905,860.32 in the same period last year[3] - The net profit attributable to shareholders for Q1 2024 was ¥13,820,019.32, down 35.57% from ¥21,450,394.62 year-on-year[3] - The basic earnings per share decreased by 40.00% to ¥0.03 from ¥0.05 in the previous year[4] - Total operating revenue for Q1 2024 was CNY 77,848,729.29, a decrease of 8.8% compared to CNY 84,905,860.32 in Q1 2023[22] - Net profit for Q1 2024 was CNY 13,672,825.17, down 36.4% from CNY 21,378,484.39 in Q1 2023[23] - Earnings per share for Q1 2024 was CNY 0.03, compared to CNY 0.05 in the same period last year[23] Cash Flow - The net cash flow from operating activities improved significantly, reaching -¥6,116,427.18, a 92.46% increase compared to -¥81,087,607.43 in the same period last year[3] - The net cash flow from operating activities for Q1 2024 was -6,116,427.18, compared to -81,087,607.43 in Q1 2023, indicating an improvement[25] - Cash inflow from financing activities was 10,000,000.00, while cash outflow totaled 1,248,000.00, resulting in a net cash flow of 8,752,000.00, compared to -2,700,000.00 in Q1 2023[26] - The company reported a total cash outflow from operating activities of 107,245,653.73, slightly lower than 110,922,849.04 in the previous year[25] Assets and Liabilities - Total assets at the end of Q1 2024 were ¥1,856,914,625.30, reflecting a 0.82% increase from ¥1,841,724,750.08 at the end of the previous year[4] - The total liabilities as of Q1 2024 were CNY 211,477,312.32, compared to CNY 209,130,888.43 in Q1 2023[21] - Total equity increased to CNY 1,645,437,312.98 from CNY 1,632,593,861.65 year-over-year[21] - The company's total current assets amount to 887,104,899.02 yuan, an increase from 853,749,802.65 yuan at the beginning of the period[19] Expenses - Total operating costs increased to CNY 65,069,836.08, up 6.8% from CNY 61,375,123.45 in the previous year[22] - The company experienced a 53.58% reduction in selling expenses, totaling ¥2,288,763.73 compared to ¥4,931,076.77 in the previous year[11] - Research and development expenses rose to CNY 18,750,970.74, an increase of 9.6% from CNY 17,108,328.96 in the previous year[22] Investments - Investment payments increased to ¥372,000,000.00, a 163.64% rise from ¥141,100,000.00 in the previous year, primarily due to increased purchases of financial products[12] - The company recorded a government subsidy income of ¥4,148,703.55, contributing to the increase in other income[6] Shareholder Information - The total number of common shareholders at the end of the reporting period is 30,133[15] - Delixi Group Co., Ltd. holds 42.47% of shares, totaling 186,087,400 shares, with 70,499,999 shares pledged and 30,000,000 shares frozen[15] Future Outlook - Future outlook includes a focus on market expansion and potential new product development to drive revenue growth[22]

广东甘化科工股份有限公司 2023年度内部控制评价报告 广东甘化科工股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部 控制监管要求（以下简称企业内部控制规范体系），结合本公司（以 下简称公司）内部控制制度和评价办法，在内部控制日常监督和专项 监督的基础上，我们对公司2023年12月31日的内部控制有效性进行了 评价。 一、重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控 制，评价其有效性，并如实披露内部控制评价报告是公司董事会的责 任。监事会对董事会建立和实施内部控制进行监督。经营层负责组织 领导企业内部控制的日常运行。公司董事会、监事会及董事、监事、 高级管理人员保证本报告内容不存在任何虚假记载、误导性陈述或重 大遗漏，并对报告内容的真实性、准确性和完整性承担个别及连带法 律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、 财务报告及相关信息真实完整，提高经营效率和效果，促进实现发展 战略。由于内部控制存在的固有局限性，故仅能为实现上述目标提供 合理保证。此外，由于情况的变化可能导致内部控制变得不恰当，或 对控制政策和程序遵循的程度降低，根据 ...

广东甘化科工股份有限公司董事会 关于会计政策变更追溯调整财务报表数据的专项说明 一、本次追溯调整的概述 广东甘化科工股份有限公司（以下简称"公司"）于2023年4月8 日披露了《关于会计政策变更的公告》（2023-14），公司依据财政部 《企业会计准则解释第 16 号》（以下简称"解释16 号"）的要求 变更会计政策，并在2023年度报告中对2022年财务报表相关项目进行 追溯调整。 二、上述会计政策变更对公司的影响 公司按照《会计准则解释第 16 号》中关于新旧衔接的相关要求 对于在首次施行第 16 号解释的财务报表列报最早期间的期初因适用 该解释的单项交易而确认的租赁负债和使用权资产，产生应纳税暂时 性差异和可抵扣暂时性差异的，将累积影响数调整财务报表列报最早 期间的期初留存收益及其他相关财务报表项目，采用追溯法调整 2022 年财务报表相关数据。上述会计政策变更对公司财务状况和经 营成果无重大影响。 三、上述会计政策变更对财务报表的影响 执行上述会计政策对公司财务报表的影响如下： 合并资产负债表和利润表 | 项 | 目 | | 2022年12月31日/2022年度 | | | --- | --- | - ...

广东甘化科工股份有限公司 2023 年度董事会工作报告 2023年度，广东甘化科工股份有限公司（以下简称"公司"）董 事会严格遵守《公司法》《证券法》等法律法规的要求，以及《公司章 程》《董事会议事规则》等相关制度的规定，本着对全体股东负责的 态度，切实履行公司及股东赋予董事会的各项职责，勤勉尽责地开展 董事会各项工作，不断规范公司法人治理结构，有效地维护和保障了 公司和全体股东的利益。董事会按照公司年初既定发展战略，积极推 动各项业务发展，促使公司保持良好发展态势。现将董事会2023年度 工作总结及2024年公司董事会重点工作计划报告如下： 一、公司 2023 年度整体经营情况 2023 年，经济形势错综复杂，产业竞争越发激烈，面对产品审价 调整，货款结算延期及下游客户需求下降等不利的各种因素，公司在 董事会的正确领导下，坚持以"强抓市场开发，推动技术创新"为中 心，把客户开发作为头等大事，把研发能力和生产水平提升作为重点 工作，围绕"强服务、强质量、强效率"三强理念，扎实推进各项工 作任务，使公司在不利的外部环境中仍保持着稳定的发展态势。 2023 年度公司共完成营业收入 3.23 亿元，同比下降 27. ...

关于广东甘化科工股份有限公司 2023 年度营业收入扣除情况的专项审核 报告 司农专字[2024123007830032 号 目 录 | 报告正文……………………………………………………1-2 | | --- | | 营业收入扣除情况表………………………………………3-4 | 一、管理层的责任 按照《深圳证券交易所股票上市规则》和《深圳证券交易所上市公司自律监 管指南第 1 号——业务办理》的有关规定编制营业收入扣除情况表是甘化科工管 理层的责任，这种责任包括保证其内容真实、准确、完整，不存在虚假记录、误 导性陈述或重大遗漏。我们的责任是在实施审核工作的基础上对甘化科工管理层 编制的营业收入扣除情况表发表专项审核意见。 二、注册会计师的责任 我们的责任是在执行鉴证工作的基础上对甘化科工管理层编制的扣除情况表 发表专项核查意见。 三、工作概述 我们按照《中国注册会计师其他鉴证业务准则第 3101 号—历史财务信息审计 或审阅以外的鉴证业务》的规定计划和实施审核工作，以对营业收入扣除情况表 是否不存在重大错报获取合理保证。在审核过程中，我们实施了包括检查会计记 录、重新计算相关项目等我们认为必要的程序。我们相信， ...

广东甘化科工股份有限公司 2023 年度审计报告 司农审字[2024]23007830012 号 | 审计报告……………………………………………… | 1-5 | | --- | --- | | 合并资产负债表……………………………………… | 1 | | 合并利润表…………………………………………… | 2 | | 合并现金流量表……………………………………… | 3 | | 合并所有者权益变动表……………………………… | 4-5 | | 母公司资产负债表…………………………………… | 6 | | 母公司利润表………………………………………… | 7 | | 母公司现金流量表…………………………………… | 8 | | 母公司所有者权益变动表…………………………… | 9-10 | | 财务报表附注………………………………………… | 11-122 | 审 计 报 告 司农审字[2024]23007830012 号 广东甘化科工股份有限公司全体股东: 一、审计意见 我们审计了广东甘化科工股份有限公司（以下简称"甘化科工"）财务报表， 包括 2023 年 12 月 31 日的合并及母公司资产负债表，202 ...

广东甘化科工股份有限公司 2023 年度内部控制审计报告 司农审字[2024]23007830089 号 目 录 内部控制审计报告…………………………………………1-2 内部控制审计报告 司农审字[2024]23007830089 号 广东甘化科工股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我 们审计了广东甘化科工股份有限公司（以下简称"甘化科工公司"）2023 年 12 月 31 日的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部 控制评价指引》的规定，建立健全和有效实施内部控制，并评价其有效性是甘化 科工公司董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的有效性发表 审计意见，并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。此外，由于 情况的变化可能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降低， 根据内部控制审计结果推测未来内部控制的有效性具有一定 ...

Financial Performance - The company's operating revenue for 2023 was approximately ¥323.28 million, a decrease of 27.42% compared to ¥445.38 million in 2022[18]. - The net profit attributable to shareholders for 2023 was approximately ¥233.07 million, reflecting a significant decline of 295.59% from ¥119.41 million in 2022[18]. - The net profit after deducting non-recurring gains and losses was approximately ¥252.64 million, a decrease of 355.62% compared to ¥99.08 million in 2022[18]. - The cash flow from operating activities for 2023 was approximately ¥42.62 million, an increase of 180.32% from a negative cash flow of ¥53.07 million in 2022[18]. - The company reported a total revenue of ¥323,277,259.89 in 2023, a decrease of 27.5% compared to ¥445,381,991.65 in 2022[23]. - The net profit attributable to shareholders was ¥-279,972,561.17 for the fourth quarter of 2023, marking a significant decline from previous quarters[28]. - The weighted average return on equity was -13.64% in 2023, down from 7.07% in 2022, indicating a substantial decrease in profitability[22]. - Total assets decreased by 8.64% to ¥1,841,724,750.08 at the end of 2023, compared to ¥2,006,682,867.51 at the end of 2022[22]. - The net assets attributable to shareholders decreased by 8.30% to ¥1,609,597,227.59 at the end of 2023, down from ¥1,754,753,747.99 in 2022[22]. - The company experienced a negative cash flow from operating activities of ¥-81,087,607.43 in 2023, contrasting with positive cash flows in previous quarters[28]. Business Focus and Strategy - The company has undergone a shift in its main business focus, now concentrating on power supply and related products, as well as high-performance special alloy materials[16]. - The company is positioned in the defense technology industry, which is expected to grow due to national defense modernization goals set for 2027 and 2035[36]. - The company aims to enhance its competitive strength by focusing on core industries and integrating resources for military and civilian applications[47]. - The company is actively expanding its market presence and focusing on the development of high-performance special alloy materials[47]. - The company aims to leverage its strong technical foundation and innovation capabilities to benefit from the evolving market landscape[101]. - The company plans to deepen its military industry focus, leveraging both organic growth and external expansion through mergers and acquisitions, while enhancing technological innovation and service quality[104]. Research and Development - The company has committed to ongoing research and development in military products, including pre-made fragments and power supplies[16]. - Research and development expenses increased by 21.65 million yuan compared to the previous year, reflecting the company's commitment to enhancing R&D capabilities[50]. - R&D expenses increased by 29.73% to ¥94,494,116.95 in 2023 from ¥72,840,111.49 in 2022, reflecting the company's focus on technology development[71]. - The number of R&D personnel increased by 7.83% to 179 in 2023 from 166 in 2022, with a higher proportion of master's degree holders[74]. - Total R&D investment accounted for 29.23% of operating revenue in 2023, up from 16.35% in 2022, indicating a significant increase in R&D focus[75]. Risk Management - The company has faced significant risks and has outlined potential risk factors and corresponding countermeasures in its report[4]. - The company emphasized the importance of risk awareness for investors regarding its future plans and strategies[4]. - The company faces risks related to military product market fluctuations, which are influenced by defense spending budgets and military policies, potentially leading to significant performance volatility[111]. - The company is addressing risks associated with raw material price volatility by analyzing price trends and diversifying procurement sources[116]. - The company has recognized the need to enhance its technological capabilities and maintain strong customer relationships to mitigate risks related to goodwill impairment and ensure stable operational performance[115]. Corporate Governance - The company adheres to legal requirements for corporate governance, ensuring independent operations from its controlling shareholder in business, assets, and finance[132]. - The company has established a complete and independent R&D, production, procurement, and sales system, maintaining the ability to operate independently[132]. - The company has a robust internal control system and governance structure, aligning with regulatory requirements[122]. - The company has established an independent human resources management department, ensuring complete autonomy in labor, personnel, and salary management[133]. - The company maintains a clear ownership structure, with full control over its assets, preventing any asset occupation by controlling shareholders[134]. Shareholder Relations - The company plans to implement a three-year shareholder return plan from 2023 to 2025[154]. - The company did not distribute cash dividends for the fiscal year 2022 due to a net loss attributable to shareholders and the necessity to retain funds for stable operations and industry expansion[173]. - The company held two shareholder meetings during the reporting period, ensuring equal treatment of all shareholders[123]. - The first temporary shareholders' meeting in 2023 had a participation rate of 35.72% and approved several proposals, including changes to the accounting firm and the repurchase of restricted stock[135]. - The annual shareholders' meeting in 2022 had a participation rate of 35.82% and approved the annual financial report and the three-year shareholder return plan for 2023-2025[135]. Management Changes - The company experienced a significant change in management, with the resignation of key personnel including the Secretary of the Board, the Vice Chairman, and the CFO due to various reasons[140]. - The company appointed a new CFO, Peng Zankai, on October 26, 2023, following the resignation of the previous CFO, Chen Bo[142]. - The company has undergone a restructuring of its executive team, which may impact future strategic directions and operational efficiency[141]. - The company’s management team has extensive backgrounds in various industries, which may contribute to its strategic decision-making processes moving forward[143]. Compliance and Internal Controls - The company has implemented a comprehensive internal control system to manage operational risks and ensure compliance with regulatory requirements[178]. - The internal control audit report issued a standard unqualified opinion, confirming effective internal controls over financial reporting as of December 31, 2023[182]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[185]. - The company has not identified any significant internal control deficiencies during the reporting period[179].